Significance of Methylation of FBP1 Gene in Non-Small Cell Lung Cancer

Table 2

Association of FBP1 DNA methylation level with clinicopathological factors in the normal tissue of patients with NSCLC.

Factors	Patients, n(%)	FBP1	P	FBP1		P
		Median (Mean, 5th-95th)		Low methylation; n( % )	High methylation; n( % )
Sex			0.566			0.430
Male	90(84.11)	2.13(2.31,1.89-2.73)		43(40.19)	47(43.93)
Female	17(15.89)	2.00(2.31,0.98-3.63)		10(9.35)	7(6.54)
Age(years)			0.277			0.423
65	77(71.96)	2.00(2.25,1.74-2.77)		40(37.38)	37(34.58)
65	30(28.04)	2.25(2.45,1.84-3.06)		13(12.15)	17(15.89)
Family History			0.016			0.653
no	87(81.31)	2.00(2.22,1.81-2.62)		44(41.12)	43(40.19)
yes	20(18.69)	2.40(2.71,1.40-4.03)		9(8.41)	11(10.28)
Smoking			0.021			0.014
Never	22(20.56)	1.58(1.41,0.97-2.22)		15(14.02)	7(6.54)
Ever/Current	85(79.44)	2.84(3.32,2.81-4.21)		33(30.84)	52(48.60)
Alcohol			0.196			0.781
Never	45(42.06)	2.00(2.28,1.67-2.89)		23(21.50)	22(20.56)
Ever/Current	62(57.94)	2.13(2.33,1.78-2.88)		30(28.04)	32(29.91)
Histologic type			0.320			0.784
Squamous cell carcinoma	37(34.58)	2.25(2.28,1.65-2.91)		19(17.76)	18(16.82)
Adenocarcinoma	70(65.42)	2.00(2.33,1.96-2.86)		34(31.78)	36(33.64)
Grade			0.118			0.916
high-middle	58(54.21)	2.00(2.09,1.60-2.58)		29(27.10)	29(27.10)
middle-low	49(45.79)	2.25(2.57,1.89-3.24)		24(22.43)	25(23.36)
Clinical stage			0.039			0.181
I - II	83(77.57)	2.00(2.24,1.79-2.70)		44(41.12)	39(36.45)
III	24 (22.43)	2.25(2.53,1.62-2.53)		9(8.41)	15(14.02)